Inflammatory bowel disease (IBD)—consisting of ulcerative colitis and Crohn's disease—is a
complex, heterogeneous, immune-mediated inflammatory condition with a multifactorial …

The past decades witnessed a significant stride in deciphering the pathophysiology of
inflammatory bowel disease, which further advanced drug development adding several new …

Precision medicine is part of 5 focus areas of the Challenges in IBD Research 2024
research document, which also includes preclinical human IBD mechanisms, environmental …

Key studies published in 2021 demonstrated mechanisms that drive macrophage–fibroblast
pathogenicity in Crohn's disease, developed multi-omics profiles to predict response to …

Crohn's disease and ulcerative colitis are increasingly prevalent, relapsing and remitting
inflammatory bowel diseases (IBDs) with variable disease courses and complications. Their …

Inflammatory bowel disease (IBD) is primarily identified by two major conditions: ulcerative
colitis (UC) and Crohn's disease (CD)[1]. These conditions can affect individuals at any age …

Introduction: Inflammatory bowel disease (IBD) is an exceptional scenario with regard to
drug targeting, as oral administration has the potential to deliver the drug directly to the site …

Inflammatory bowel diseases comprising Crohn's disease and ulcerative colitis have
emerged as global diseases. Multiple distinct therapeutic mechanisms have allowed us to …

Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease
(CD), is a class of severe and chronic diseases of the gastrointestinal (GI) tract with recurrent …

Despite progress in recent decades, patients with inflammatory bowel diseases face many
critical unmet needs, demonstrating the limitations of available treatment options …